Choksi Laboratories (CHOKSILA) | Financial Analysis & Statements
Choksi Laboratories Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
108.2M
Gross Profit
87.1M
80.48%
Operating Income
8.0M
7.40%
Net Income
3.1M
2.87%
EPS (Diluted)
₹0.45
Balance Sheet Metrics
Total Assets
652.4M
Total Liabilities
407.4M
Shareholders Equity
244.9M
Debt to Equity
1.66
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Choksi Laboratories Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 417.8M | 367.0M | 344.4M | 300.4M | 256.9M |
| Cost of Goods Sold | 46.2M | 37.2M | 33.8M | 28.3M | 35.1M |
| Gross Profit | 371.6M | 329.7M | 310.6M | 272.1M | 221.8M |
| Gross Margin % | 88.9% | 89.9% | 90.2% | 90.6% | 86.3% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 12.6M | 11.6M | 11.1M | 7.8M | 7.8M |
| Other Operating Expenses | 68.7M | 63.2M | 56.9M | 50.3M | 51.1M |
| Total Operating Expenses | 81.3M | 74.8M | 68.1M | 58.0M | 59.0M |
| Operating Income | 50.1M | 47.2M | 49.5M | 36.6M | -3.0M |
| Operating Margin % | 12.0% | 12.9% | 14.4% | 12.2% | -1.2% |
| Non-Operating Items | |||||
| Interest Income | 598.0K | 1.6M | 2.0M | 1.2M | 4.4M |
| Interest Expense | 26.6M | 30.1M | 34.9M | 32.1M | 28.0M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 21.5M | 16.6M | 37.2M | 3.7M | -28.1M |
| Income Tax | 6.3M | 5.5M | 5.1M | 1.6M | -2.0M |
| Effective Tax Rate % | 29.3% | 33.3% | 13.7% | 43.6% | 0.0% |
| Net Income | 15.2M | 11.1M | 32.1M | 2.1M | -26.1M |
| Net Margin % | 3.6% | 3.0% | 9.3% | 0.7% | -10.2% |
| Key Metrics | |||||
| EBITDA | 115.1M | 105.4M | 106.4M | 91.8M | 47.0M |
| EPS (Basic) | ₹2.19 | ₹1.59 | ₹4.61 | ₹0.30 | ₹-3.74 |
| EPS (Diluted) | ₹2.19 | ₹1.59 | ₹4.61 | ₹0.30 | ₹-3.74 |
| Basic Shares Outstanding | 6965000 | 6965000 | 6965000 | 6965000 | 6965000 |
| Diluted Shares Outstanding | 6965000 | 6965000 | 6965000 | 6965000 | 6965000 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Choksi Laboratories Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 6.1M | 6.6M | 3.4M | 4.1M | 3.1M |
| Short-term Investments | 1.2M | 4.3M | 4.2M | 662.0K | 576.0K |
| Accounts Receivable | 112.7M | 103.9M | 106.5M | 102.9M | 81.6M |
| Inventory | 5.6M | 3.6M | 2.1M | 2.5M | 1.1M |
| Other Current Assets | 1.0K | 1.0K | 6.2M | -1.0K | -1.0K |
| Total Current Assets | 163.2M | 145.7M | 139.5M | 140.1M | 130.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 471.3M | 36.1M | 36.1M | 36.1M | 36.1M |
| Goodwill | 4.8M | 3.6M | 3.9M | 3.2M | 2.9M |
| Intangible Assets | 4.8M | 3.6M | 3.9M | 3.2M | 2.9M |
| Long-term Investments | 0 | 0 | 0 | - | - |
| Other Non-Current Assets | 141.0K | 2.0K | 1.0K | 909.0K | 2 |
| Total Non-Current Assets | 490.1M | 473.8M | 464.2M | 504.1M | 533.5M |
| Total Assets | 653.3M | 619.5M | 603.6M | 644.2M | 663.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 54.3M | 39.3M | 18.0M | 40.2M | 48.3M |
| Short-term Debt | 131.9M | 117.9M | 72.0M | 76.9M | 78.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 664.0K | 706.0K | 867.0K | 1.6M | 436.0K |
| Total Current Liabilities | 238.8M | 188.5M | 125.1M | 155.2M | 162.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 159.6M | 190.8M | 252.1M | 296.0M | 313.5M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -1.0K | -1.0K | -1.0K | - | - |
| Total Non-Current Liabilities | 178.5M | 208.9M | 267.4M | 309.9M | 324.1M |
| Total Liabilities | 417.3M | 397.4M | 392.6M | 465.1M | 486.3M |
| Equity | |||||
| Common Stock | 69.7M | 69.7M | 69.7M | 69.7M | 69.7M |
| Retained Earnings | 150.6M | 135.3M | 124.2M | 92.2M | 90.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 236.0M | 222.1M | 211.1M | 179.0M | 177.5M |
| Key Metrics | |||||
| Total Debt | 291.6M | 308.7M | 324.2M | 372.9M | 391.5M |
| Working Capital | -75.5M | -42.8M | 14.3M | -15.1M | -31.9M |
Balance Sheet Composition
Choksi Laboratories Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 21.5M | 16.6M | 37.2M | 3.7M | -28.1M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | 3.9M | -8.4M | -12.5M | -18.0M | -4.0M |
| Operating Cash Flow | 51.4M | 36.6M | 35.0M | 16.6M | -8.8M |
| Investing Activities | |||||
| Capital Expenditures | -74.4M | -69.1M | -7.1M | -26.4M | -80.5M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | 197.0K | 1.9M | 52.0K | - | - |
| Investing Cash Flow | -74.2M | -67.2M | -7.0M | -26.4M | -80.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 38.4M | 310.1M | 20.0M | 26.7M | 47.3M |
| Debt Repayment | -58.7M | -363.7M | -55.1M | -41.3M | -11.2M |
| Financing Cash Flow | -10.5M | -11.1M | -36.6M | -14.5M | 36.1M |
| Free Cash Flow | 40.9M | 44.6M | 41.0M | 50.1M | -22.0M |
| Net Change in Cash | -33.3M | -41.8M | -8.6M | -24.3M | -53.2M |
Cash Flow Trend
Choksi Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
37.71
Price to Book
2.85
Price to Sales
1.58
PEG Ratio
0.19
Profitability Ratios
Profit Margin
4.17%
Operating Margin
7.41%
Return on Equity
6.45%
Return on Assets
2.33%
Financial Health
Current Ratio
0.74
Debt to Equity
120.16
Beta
0.06
Per Share Data
EPS (TTM)
₹2.68
Book Value per Share
₹35.41
Revenue per Share
₹64.40
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CHOKSILA | 703.8M | 37.71 | 2.85 | 6.45% | 4.17% | 120.16 |
| Dr. Lal PathLabs | 238.9B | 46.16 | 10.20 | 22.08% | 19.84% | 6.44 |
| Sai Life Sciences | 217.1B | 64.75 | 9.48 | 7.99% | 15.34% | 18.40 |
| Vimta Labs | 20.5B | 28.76 | 5.13 | 17.78% | 18.82% | 1.63 |
| Krsnaa Diagnostics | 19.8B | 24.69 | 2.13 | 8.79% | 10.49% | 30.96 |
| Suraksha Diagnostic | 14.7B | 45.27 | 6.37 | 15.14% | 11.32% | 51.30 |
Financial data is updated regularly. All figures are in the company's reporting currency.





